Drug intelligence / Profile preview

3328zT2

Development stage: Preclinical
Lead developer: Wellington Zhaotai Therapies
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

3328zT2 is an investigational chimeric antigen receptor (CAR) T-cell therapy developed by Wellington Zhaotai. The therapy is engineered to target CD33 (Siglec-3), a transmembrane receptor expressed on the surface of myeloid lineage cells and frequently overexpressed in myeloid leukemias. The CAR construct features a CD28 co-stimulatory domain and a CD3-zeta signaling domain, a configuration designed to promote rapid T-cell activation and robust effector function. Currently in the preclinical stage, 3328zT2 is being evaluated for its potential in treating Acute Myeloid Leukaemia (AML) and Multiple Myeloma.

Other names: Wellington Zhaotai CD33 CAR-T

Targets

CD33 (Myeloid cell surface antigen CD33)

Beyond the preview

Go deeper on 3328zT2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3328zT2.

Explore the full profile